Spectral Diagnostics (Canada) acquires septic shock rights:
This article was originally published in Clinica
Executive Summary
Spectral Diagnostics (Canada) has acquired patent-pending technology for early septic shock detection. The royalty- bearing deal also includes a collaborative research agreement with the Toronto Hospital team that developed the test. Spectral intends to develop a point-of-care test for critical care unit use. Septic shock affects around 400,000 North Americans every year. Treatment costs $5-10,000 million in the US alone.